应用 ATP 肿瘤化疗药敏检测评估食管癌的化疗敏感性异质性。
Heterogeneity of chemosensitivity in esophageal cancer using ATP-tumor chemosensitivity assay.
机构信息
Zhejiang Cancer Research Institute, Zhejiang Province Cancer Hospital, Zhejiang Cancer Center, Hangzhou, China.
出版信息
Acta Pharmacol Sin. 2012 Mar;33(3):401-6. doi: 10.1038/aps.2011.195. Epub 2012 Jan 30.
AIM
Current chemotherapy for esophageal cancer is conducted on the basis of empirical information from clinical trials, which fails to take into account the known heterogeneity of chemosensitivity between patients. This study was aimed to demonstrate the degree of heterogeneity of chemosensitivity in esophageal cancers.
METHODS
A total of 42 esophageal cancer specimens were collected. The heterogeneity of chemosensitivity in esophageal cancer specimens was examined using an ex vivo ATP-tumor chemosensitivity assay (ATP-TCA).
RESULTS
Thirty eight specimens produced evaluable results (90.5%). The most active single agent tested was nedaplatin, to which 28.9% of samples were sensitive. Combinations of chemotherapy agents exhibited much higher sensitivity: cisplatin + paclitaxel was sensitive in 16 of 38 (42.1%) of samples, while nedaplatin+paclitaxel was more effective, which was sensitive in 20 of 38 cases (52.6%).
CONCLUSION
There was a marked heterogeneity of chemosensitivity in esophageal cancer. Chemosensitivity testing may provide a practical method for testing new regimens before clinical trials in esophageal cancer patients.
目的
目前的食管癌化疗是基于临床试验的经验信息进行的，未能考虑到患者之间已知的化疗敏感性异质性。本研究旨在展示食管癌化疗敏感性的异质性程度。
方法
共收集了 42 例食管癌标本。使用体外 ATP-肿瘤化疗敏感性检测（ATP-TCA）检测食管癌标本的化疗敏感性异质性。
结果
38 例标本产生了可评估的结果（90.5%）。检测到的最活跃的单一药物是奈达铂，28.9%的样本对此药物敏感。化疗药物联合使用显示出更高的敏感性：顺铂+紫杉醇在 38 例样本中的 16 例（42.1%）中敏感，而奈达铂+紫杉醇更有效，在 38 例样本中的 20 例（52.6%）中敏感。
结论
食管癌存在明显的化疗敏感性异质性。化疗敏感性检测可能为食管癌患者在临床试验前测试新方案提供一种实用方法。
Zotero 插件